Ford AL, Hunt LP, Cooper A, Shield JP
In January 2025, the Food and Drug Administration (FDA) approved a brand of semaglutide to reduce the risk of both cardiovascular death and worsening kidney disease in people with Type 2 diabetes and chronic kidney disease
Clinical Access & Oversight Good Once youre a patient, clinical access is strong
At moderate oxidative stress this effect small
Reduces Chronic Inflammation Inflammation is one of the most common root causes of pain and disease
Additionally, LPS itself, along with other inflammation-inducing agents zymosan and turpentine, were found to increase hepatic PCSK9 mRNA levels (Feingold et al., 2008), suggesting that these pathogens utilize increased PCSK9 levels to promote their virulence and may be combatted by PCSK9 downregulation